Pyoderma Gangrenosum – Cannabis Research

Pyoderma Gangrenosum Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 1 studies associated with Pyoderma Gangrenosum.

Here is a small sampling of Pyoderma Gangrenosum studies by title:

Components of the Pyoderma Gangrenosum Research Dashboard

  • Dosing information available for Pyoderma Gangrenosum
  • Chemotype guidance for treating Pyoderma Gangrenosum with cannabis
  • Synopsis of cannabis research for Pyoderma Gangrenosum
  • Individual study details for Pyoderma Gangrenosum

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Pyoderma Gangrenosum

Description of Pyoderma Gangrenosum

The term pyoderma gangrenosum describes a destructive skin condition of deep localized damage to the affected tissue that can be associated with systemic diseases or trauma (e.g. surgical sites). More specifically, it is a is a relatively rare inflammatory neutrophilic skin disease affecting most commonly the skin of the lower extremities but also the gut such as in the setting of inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or certain tumors for example. Resulting ulceration takes place with degrees of tissue death that makes healing chronically difficult. Within allopathic medicine the precise causes of this condition are subject to ongoing investigation but still poorly understood but is considered to potentially be of autoimmune origins or have a genetic component to it. Unless the underlying pathologies are addressed effectively the condition tends to be chronic in nature and very resistant to healing. If the conditions continue to degrade gangrene will set in making surgical excision or amputation a necessity. While the exact causes are not fully understood cellular observations have shown an imbalance of a number of pro- and anti- inflammatory cytokines. Pyoderma Gangrenosum is not contagious.

Disease Classification

Condition: Gangrene
Disease Family: Autoimmune Disorder
Organ System: Integumentary System
ICD-10 Chapter: Diseases of the Skin and Subcutaneous Tissue
ICD-10 Code: L88

Pyoderma Gangrenosum Symptoms:

Start with localized inflammation, progresses to chronic necrotic tissue/ulcers (e.g. skin, gut), gangrene, pain and inflammation (red, swollen, heat) at surrounding tissue sites

Also known as:

PD, Gangrene, Pyoderma vegetans, Dermatitis vegetans

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.